TrialJournal of the European Academy of Dermatology and Venereology : JEADV2022

Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate-to-severe atopic dermatitis: an analysis of patient-reported outcomes.

M J Cork et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.